Trial Profile
A phase I/II study of CellProtect in patients with multiple myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2020
Price :
$35
*
At a glance
- Drugs Natural killer cell therapy (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 22 Dec 2017 New trial record
- 15 Dec 2017 According to a CellProtect Nordic Pharmaceuticals AB, media release, the work on a clinical trial report to the Swedish Medical Products Agency is on-going and the plan is to publish the results in 2018.